EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. - IMUC

NEW YORK, June 14, 2017

To join the ImmunoCellular class action, go to http://rosenlegal.com/cases-1115.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well. As a result of this scheme, ImmunoCellular's share price was artificially inflated. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1115.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.